Cidara Therapeutics Inc’s recent filing unveils that its Director RA CAPITAL MANAGEMENT, L.P. acquired Company’s shares for reported $100.0 million on Jun 26 ’25. In the deal valued at $44.00 per share,2,272,727 shares were bought. As a result of this transaction, RA CAPITAL MANAGEMENT, L.P. now holds 3,365,523 shares worth roughly $208.43 million.
Then, Mineo Chrysa bought 2,270 shares, generating $49,281 in total proceeds. Upon buying the shares at $21.71, the Director now owns 2,270 shares.
Before that, Mineo Chrysa bought 1,050 shares. Cidara Therapeutics Inc shares valued at $24,614 were divested by the Director at a price of $23.44 per share. As a result of the transaction, Mineo Chrysa now holds 3,320 shares, worth roughly $0.21 million.
A number of analysts have revised their coverage, including Citizens JMP’s analysts, who began to cover the stock in mid March with a ‘”a Mkt outperform”‘ rating. RBC Capital Mkts started covering the stock on December 13, 2024. It rated CDTX as “an Outperform”.
Price Performance Review of CDTX
On Tuesday, Cidara Therapeutics Inc [NASDAQ:CDTX] saw its stock fall -1.20% to $61.93. Over the last five days, the stock has gained 0.65%. Cidara Therapeutics Inc shares have risen nearly 418.24% since the year began. Nevertheless, the stocks have risen 130.39% over the past one year. While a 52-week high of $66.94 was reached on 07/23/25, a 52-week low of $10.14 was recorded on 04/07/25.
Levels Of Support And Resistance For CDTX Stock
The 24-hour chart illustrates a support level at 60.91, which if violated will result in even more drops to 59.89. On the upside, there is a resistance level at 63.06. A further resistance level may holdings at 64.19.
How much short interest is there in Cidara Therapeutics Inc?
A steep rise in short interest was recorded in Cidara Therapeutics Inc stocks on 2025-07-15, growing by 1.62 million shares to a total of 2.27 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 0.65 million shares. There was a rise of 71.38%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on November 08, 2024 when Guggenheim began covering the stock and recommended ‘”a Buy”‘ rating along with a $33 price target.
